Tissue-agnostic cancer drug

Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear.[1][2][3] Tissue-agnostic drugs include Pembrolizumab (Keytruda) and Larotrectinib (Vitrakvi).[2] [4]

History

Petrolizumab was approved by the US Food and Drug Administration In May 2017.[5]

Larotrectinib was approved by the FDA in November, 2018.[5]

Loxo-292 received priority review in September 2018.[5]

Other drugs under development include Entrectinib, BLU-667, Loxo-195 and Anti-ERBB3 antibody.[5]

References
  1. Bacon, John (28 November 2018). "FDA approves new drug reflecting cutting-edge, 'tissue-agnostic' effort to beat cancer". USA Today. Retrieved 3 December 2018.
  2. Garber, Ken (16 June 2017). "In a major shift, cancer drugs go 'tissue-agnostic'". Science. 356 (6343): 1111–1112. doi:10.1126/science.356.6343.1111. PMID 28619894.
  3. Garber, Ken (16 June 2017). "Tissue-agnostic cancer drug pipeline grows, despite doubts". Nature. 17 (4): 227–229. doi:10.1038/nrd.2018.6. PMID 29520093.
  4. Dun, Lauren (27 Nov 2018). "FDA approves a new cancer drug targeted to genetic mutation, not cancer type". NBC. Retrieved 17 Dec 2018.
  5. Wang, Brian (June 19, 2019). "New Gene Targeting Cancer Drugs And Other Advances in Cancer Medicine – NextBigFuture.com". www.nextbigfuture.com. Retrieved 2019-06-19.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.